Vaccine Developers to Create Affordable Products for Emerging Markets

Vaccine Developers to Create Affordable Products for Emerging Markets

Wednesday, 27 February 2008

Increased global travel has caused several infectious diseases, such as Yellow Fever and West Nile Virus, to surface in developed countries that were previously only common to emerging and underdeveloped areas. This has opened up a channel for vaccine manufacturers to develop products for advanced countries.

New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), U.S. Infectious Diseases Vaccine Pipeline, covers an extensive list of 22 diseases.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the U.S. Infectious Diseases Vaccine Pipeline, then send an e-mail to Melina Trevino, Corporate Communications, at [email protected], with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you via e-mail.

"Relatively unknown diseases have made their way to the top of vaccine developers' priority lists, enhancing the pipelines for infectious diseases' vaccines," says Frost & Sullivan Research Analyst Barath Shankar S. "The developers of these vaccines seek to cash in on the opportunities provided by the spread of diseases through accelerated vaccine development."

Several vaccine pipelines have become very robust for infectious diseases targeted at developing and underdeveloped markets. While vaccine developers feel a sense of responsibility to keep these products affordable in a large-scale market, even basic healthcare has become largely inaccessible in these underdeveloped markets and most often do not attain the funds to acquire vaccines at innovator prices.

While vaccine companies could sell in markets where they can obtain optimum prices for their products, it may not be feasible for them to develop in these underdeveloped markets. Doing this could actually deter companies from expanding their manufacturing capacities in order to cater to alternate markets.

"Future growth of the vaccines market is tied to its performance in emerging markets, where the need for vaccines is substantial," notes Barath Shankar. "Hence, it is important for innovators to partner with companies that have a strong regional presence and the ability to produce vaccines at a low cost to ensure affordability."

Increased collaboration and licensing of technology platforms can also significantly aid market growth.

U.S. Infectious Diseases Vaccine Pipeline is part of the Pharmaceutical & Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: global vaccines markets, European vaccines market, and global biopharmaceutical contract manufacturing markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.